Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials
| Autor: | Fabio Sonvico, Aline de Cristo Soares Alves, Silvia Stanisçuaski Guterres, Tanira Aguirre, Adriana Raffin Pohlmann, Franciele Aline Bruinsmann, Gustavo Richter Vaz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty clinical evaluation medicine.medical_treatment Brain tumor Pharmaceutical Science Antineoplastic Agents Context (language use) Review Analytical Chemistry glioblastoma multiforme 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Internal medicine Drug Discovery medicine Animals Humans pre-clinical studies Physical and Theoretical Chemistry Administration Intranasal oncology_oncogenics 030304 developmental biology 0303 health sciences Temozolomide Brain Neoplasms business.industry nasal delivery Standard treatment Organic Chemistry Brain medicine.disease Clinical trial Radiation therapy Nasal Mucosa Blood-Brain Barrier Chemistry (miscellaneous) 030220 oncology & carcinogenesis drug delivery Drug delivery nose-to-brain delivery Molecular Medicine nanoparticles Nasal administration Glioblastoma business medicine.drug |
| Zdroj: | Molecules |
| Popis: | Glioblastoma (GBM) is the most lethal form of brain tumor, being characterized by the rapid growth and invasion of the surrounding tissue. The current standard treatment for glioblastoma is surgery, followed by radiotherapy and concurrent chemotherapy, typically with temozolomide. Although extensive research has been carried out over the past years to develop a more effective therapeutic strategy for the treatment of GBM, efforts have not provided major improvements in terms of the overall survival of patients. Consequently, new therapeutic approaches are urgently needed. Overcoming the blood–brain barrier (BBB) is a major challenge in the development of therapies for central nervous system (CNS) disorders. In this context, the intranasal route of drug administration has been proposed as a non-invasive alternative route for directly targeting the CNS. This route of drug administration bypasses the BBB and reduces the systemic side effects. Recently, several formulations have been developed for further enhancing nose-to-brain transport, mainly with the use of nano-sized and nanostructured drug delivery systems. The focus of this review is to provide an overview of the strategies that have been developed for delivering anticancer compounds for the treatment of GBM while using nasal administration. In particular, the specific properties of nanomedicines proposed for nose-to-brain delivery will be critically evaluated. The preclinical and clinical data considered supporting the idea that nasal delivery of anticancer drugs may represent a breakthrough advancement in the fight against GBM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|